GRAIL, Inc. (GRAL) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

14/25

Growth 4 Margin 2 Expansion 3 Platform 3 Financial 2

latest quarter score

Earnings Reports

14
Grail (GRAL) Q2 2026: Gallery Test Volumes Jump 35% as FDA Approval Becomes Market Catalyst
August 06, 2026
15
Grail (GRAL) Q1 2026: Gallery Test Volume Jumps 50% as Health System Integrations Accelerate
May 06, 2026
16
Grail (GRAL) Q4 2025: Gallery Test Volume Up 36% as Stage 4 Cancer Detection Drops Over 20%
February 23, 2026
17
GRAIL (GRAL) Q3 2025: 55% Margin Expansion Underscores Fixed Cost Leverage Ahead of FDA Milestone
November 14, 2025
14
Grail (GRAL) Q2 2025: Gallery Repeat Testing Climbs to 25%, Powering Evidence-Driven Expansion
August 13, 2025
19
Grail (GRAL) Q1 2025: Cash Burn Down 40% as Automation Drives Margin Gains
July 06, 2025

Browse all companies